Tuesday, Human Genome Sciences, Inc. (HGSI) said, as expected, it received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration, or FDA, regarding the company's Biologics License Application, or BLA, for 900-mcg ZALBIN dosed every two weeks for treating chronic hepatitis C.
HGS and Novartis decided not to develop ZALBIN further.
HGS, Human Genome Sciences and ZALBIN are trademarks of Human Genome Sciences, Inc.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.